Silver Book Fact

Annual AFib-related stroke Medicare costs

Stroke in Medicare patients with atrial fibrillation who were not treated with anticoagulants, cost Medicare $4.8 billion each year in direct costs. Those who had strokes despite prophylactic treatment cost an additional $3.1 billion.

Caro, JJ. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation. Am J Managed Care. 2004; 10(14): S451-61. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation

Reference

Title
An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation
Publication
Am J Managed Care
Publication Date
2004
Authors
Caro, JJ
Volume & Issue
Volume 10, Issue 14
Pages
S451-61
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Hospital costs for ischemic stroke
    Hospital costs for nonrecurrent ischemic stroke are 20% higher in patients with atrial fibrillation, than in patients without the disease.  
  • AFib, an economic burden
    AFib is a major economic burden for the U.S. with at least $6.65 billion in healthcare costs attributable to the disease each year. This estimate may be low. One study…  
  • Projected AFib prevalence
    Projected increases in the prevalence of Afib  
  • Cost of AFib-related stroke in Medicare patients
    The incremental treatment costs associated with stroke in the year following diagnosis of atrial fibrillation are an estimated $7,907 per Medicare patient.  
  • Atrial fibrillation stroke risk
    Atrial fibrillation (AF) increases the risk of severe and recurrent ischemic stroke. Patients not treated with anticoagulants have a 2.1-fold increase in risk of recurrent stroke and 2.4-fold increase in…